Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARYAlan J. Garber, Guillermo E. Umpierrez, Martin J. Abrahamson et al.|Endocrine Practice|2016Cited by 875
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive SummaryYehuda Handelsman, Farhad Zangeneh, Guillermo E. Umpierrez et al.|Endocrine Practice|2015Cited by 633
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive SummaryAlan J. Garber, Guillermo E. Umpierrez, Yehuda Handelsman et al.|Endocrine Practice|2020Cited by 603
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595
American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015Yehuda Handelsman, Farhad Zangeneh, Zachary T. Bloomgarden et al.|Endocrine Practice|2015Cited by 565